Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Envafolimab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascletis Announces Positive Data from Phase IIb Expansion Cohort of ASC22
    Ascletis Announces Positive Data from Phase IIb Expansion Cohort of ASC22

    28 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-positive-interim-data-from-the-phase-iib-expansion-cohort-of-asc22-envafolimab-for-chronic-hepatitis-b-functional-cure-301941562.html

    PR NEWSWIRE
    28 Sep 2023
    Share Share
    Clinical Results of ASC22 in Combination with Chidamide Presented at 12th IAS
    Clinical Results of ASC22 in Combination with Chidamide Presented at 12th IAS

    24 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/clinical-results-of-asc22-envafolimab-in-combination-with-chidamide-for-functional-cure-of-hiv-infection-presented-at-the-12th-ias-conference-on-hiv-science-301884101.html

    PR NEWSWIRE
    24 Jul 2023
    Share Share
    TRACON Pharma Announces Positive Results Based on Ongoing Double-Digit Objective
    TRACON Pharma Announces Positive Results Based on Ongoing Double-Digit Objective

    20 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/20/2691010/10391/en/TRACON-Pharmaceuticals-Announces-Positive-Results-Based-on-Ongoing-Double-Digit-Objective-Response-Rate-for-Single-Agent-Envafolimab-in-the-ENVASARC-Phase-2-Pivotal-Trial.html

    GLOBENEWSWIRE
    20 Jun 2023
    Share Share
    Ascletis Announces Dosing of the First Patient in the Phase IIb of ASC22
    Ascletis Announces Dosing of the First Patient in the Phase IIb of ASC22

    27 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-dosing-of-the-first-patient-in-the-phase-iib-expansion-cohort-of-asc22-envafolimab-for-chronic-hepatitis-b-functional-cure-301634508.html

    PRNEWSWIRE
    27 Sep 2022
    Share Share
    Biocytogen and Tracon get FDA IND clearance for Phase I/II sarcoma trial
    Biocytogen and Tracon get FDA IND clearance for Phase I/II sarcoma trial

    30 Aug 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/biocytogen-tracon-sarcoma-trial/

    CLINICALTRIALSARENA
    30 Aug 2022
    Share Share
    US FDA Approval of IND for CTLA-4 Antibody YH001
    US FDA Approval of IND for CTLA-4 Antibody YH001

    29 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220829005548/en

    BUSINESSWIRE
    29 Aug 2022
    Share Share